24/7 Market News Snapshot 16 October, 2025 – Personalis, Inc. Common Stock (NASDAQ:PSNL)

October 16, 2025

DENVER, Colo., 16 October, 2025 (www.247marketnews.com) – (NASDAQ:PSNL) are discussed in this article.
Personalis, Inc. has experienced a notable surge in its stock value, beginning the trading day at $8.58 before reaching a high of $9.85, reflecting an impressive increase of approximately 15.47% from its previous close of $8.53. With a current trading volume of 2.08 million shares, the activity indicates heightened investor interest and emerging market trends that could signal potential volatility. Investors are advised to keep a close watch on critical resistance levels around $10.00 and support thresholds around $8.50 to inform future investment decisions.

In conjunction with this market performance, Personalis has unveiled significant progress in its clinical research endeavors. The company, which specializes in precision oncology solutions, has announced pivotal outcomes from a phase 3 clinical trial executed in partnership with AstraZeneca. This trial examined the effectiveness of Personalis’ molecular residual disease (MRD) test, NeXT Personal®, in monitoring treatment responses in patients suffering from unresectable EGFR-mutated non-small cell lung cancer (NSCLC) after undergoing chemoradiotherapy (CRT).

Findings from the AstraZeneca-led LAURA trial underscore the efficacy of NeXT Personal in tracking treatment response, as it demonstrated the capacity to achieve MRD clearance in patients who received osimertinib therapy. Impressively, NeXT Personal was able to identify MRD progression with a median lead time of five months compared to assessments made by the Blinded Independent Central Review (BICR), evidencing its potential to significantly improve clinical outcomes.

Richard Chen, Chief Medical Officer and EVP of R&D at Personalis, has acknowledged the collaborative nature of these achievements, noting that the study highlights the advantages of their ultrasensitive ctDNA detection technology. This innovative approach not only tracks treatment response but further enhances overall cancer management strategies. Personalis remains at the forefront of precision medicine, continuously striving to provide advanced genomic profiling tailored to patient-specific needs.

Related news for (PSNL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.